AGTR2 and Parkinson disease: Additionally, a study showed that the decrease in dopamine levels observed in early stages of Parkinson’s disease and aging may promote neuroinflammation through increased AT1 expression with simultaneous decrease in AT2 expression while also affecting the regulation of RAAS activity in microglia by upregulation of the astrocyte-derived angiotensin II as well as via dopamine-induced regulation of microglial angiotensin receptors [25].